Would Gilead Sciences Make This Staggeringly Audacious Move?

Would Gilead Sciences Make This Staggeringly Audacious Move?


Gilead's CEO, John Milligan, has indicated a preference for buying another biotech to bolster his company's oncology portfolio. However, Milligan has also stated that inflammation and non-alcoholic steatohepatitis could be other areas that Gilead would like to beef up.



from Biotech News